On July 22, 2025, Jefferies analyst Roger Song announced a significant adjustment in the price target for Replimune Group (REPL, Financial), lowering it from a previous $31.00 to $6.00 USD. Despite this substantial decrease, the rating for Replimune Group (REPL) remains at 'Buy'.
The change in price target represents an 80.65% reduction, reflecting Jefferies' reassessment of the company's valuation. However, the decision to maintain the 'Buy' rating indicates continued confidence in Replimune Group's overall potential and market prospects.
Investors in Replimune Group (REPL, Financial) are advised to take note of these developments as they assess their investment strategies in light of the new price target set by Jefferies.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 7 analysts, the average target price for Replimune Group Inc (REPL, Financial) is $22.71 with a high estimate of $31.00 and a low estimate of $17.00. The average target implies an upside of 665.05% from the current price of $2.97. More detailed estimate data can be found on the Replimune Group Inc (REPL) Forecast page.
Based on the consensus recommendation from 9 brokerage firms, Replimune Group Inc's (REPL, Financial) average brokerage recommendation is currently 1.7, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
